SC 13G: GILEAD SCIENCES, INC.

Ticker: GILD · Form: SC 13G · Filed: 2024-04-19T00:00:00.000Z

Sentiment: neutral

Topics: sc-13g

AI Summary

SC 13G filing by GILEAD SCIENCES, INC..

Risk Assessment

Risk Level: low

From the Filing

0001193125-24-102955.txt : 20240419 0001193125-24-102955.hdr.sgml : 20240419 20240419163126 ACCESSION NUMBER: 0001193125-24-102955 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240419 DATE AS OF CHANGE: 20240419 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LEAP THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001509745 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 274412575 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-90188 FILM NUMBER: 24858232 BUSINESS ADDRESS: STREET 1: 47 THORNDIKE STREET STREET 2: SUITE B1-1 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617 252 4343 MAIL ADDRESS: STREET 1: 47 THORNDIKE STREET STREET 2: SUITE B1-1 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Dekkun Corp DATE OF NAME CHANGE: 20110107 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 SC 13G 1 d791510dsc13g.htm SC 13G SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K101 (CUSIP Number) April 10, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP NO. 52187K101  1   NAMES OF REPORTING PERSONS  Gilead Sciences, Inc.  2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) ☐  (b) ☐  3  SEC USE ONLY  4  CITIZENSHIP OR PLACE OF ORGANIZATION  Delaware NUMBER OF SHARES BENEFICIALLY  OWNED BY E ACH REPORTING PERSON WITH 5   SOLE VOTING POWER  5,319,148 6  SHARED VOTING POWER  0 7  SOLE DISPOSITIVE POWER  5,319,148 8  SHARED DISPOSITIVE POWER  0  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  5,319,148 10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐ 11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  13.9% (1) 12  TYPE OF REPORTING PERSON*  CO (1) Based on 25,603,471 shares of the common stock, par value $0.001 (the Common Stock) of Leap Therapeutics, Inc. (the Issuer) issued and outstanding as of April 9, 2024, plus (A) 5,319,148 shares of Common Stock issued to the Reporting Person and (B) 7,341,845 shares of Common Stock issued to other investors, in each case on